CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award 10b5-1 | +130,000 | 481,239 | ||
| 2025-01-31 | Dube Eric M CHIEF EXECUTIVE OFFICER | Grant or award · Employee stock option (right to buy) 10b5-1 | +260,000 | 260,000 | ||
| 2025-01-31 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award 10b5-1 | +30,000 | 89,443 | ||
| 2025-01-31 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award · Employee stock option (right to buy) 10b5-1 | +100,000 | 100,000 | ||
| 2025-01-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award | +21,500 | 127,874 | ||
| 2025-01-31 | Heerma Peter CHIEF COMMERCIAL OFFICER | Grant or award · Employee stock option (right to buy) | +58,000 | 58,000 | ||
| 2025-01-31 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award | +21,500 | 95,230 | ||
| 2025-01-31 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award · Employee stock option (right to buy) | +58,000 | 58,000 | ||
| 2025-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award | +13,000 | 67,002 | ||
| 2025-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award · Employee stock option (right to buy) | +26,000 | 26,000 | ||
| 2025-01-23 | Baynes Roy D. Director | Option exercise 10b5-1 | +16,000 | $17.50 | $280K | 47,000 |
| 2025-01-23 | Baynes Roy D. Director | Sale 10b5-1 | −16,000 | $20.00 | $320K | 31,000 |
| 2025-01-23 | Baynes Roy D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −16,000 | 0 | ||
| 2025-01-22 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale 10b5-1 | −2,437 | $19.46 | $47K | 83,170 |
| 2025-01-22 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −10,736 | $19.46 | $209K | 351,239 |
| 2025-01-22 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale 10b5-1 | −2,437 | $19.46 | $47K | 76,933 |
| 2025-01-22 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −1,584 | $18.94 | $30K | 106,374 |
| 2025-01-22 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −865 | $18.94 | $16K | 73,730 |
| 2025-01-22 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale | −925 | $18.94 | $18K | 54,002 |
| 2025-01-06 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −440 | $18.76 | $8K | 59,443 |
Page 21 of 51 · 1,020 trades